Celldex Therapeutics, Inc.

Celldex Therapeutics is a biopharmaceutical company that investigates mast cell biology and develops therapeutic antibody treatments. Its product pipeline consists of monoclonal and bispecific antibodies designed to treat severe inflammatory, allergic, and autoimmune conditions. The company's lead drug candidate is barzolvolimab, a monoclonal antibody that inhibits the KIT receptor to reduce mast cell activity across multiple skin disorders. It also develops CDX-622, a bispecific antibody candidate targeting inflammatory pathways. Celldex Therapeutics aims to serve patients suffering from severe mast cell-mediated diseases, including chronic spontaneous urticaria, chronic inducible urticaria, prurigo nodularis, and atopic dermatitis.

The company's clinical research spans global operations, conducting studies across 43 countries and more than 500 clinical sites. Specific trial locations mentioned include medical centers in Germany and the United States, with Phase 2 studies encompassing approximately 75 to 85 sites across up to 12 countries. The provided text does not state the location of the company's headquarters.

Summary of the business section of Celldex Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 198 full-time employees, 30 of whom have Ph.D.”